PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Pfizer, BioNTech win EU authorisation for COVID-19 vaccine Comirnaty

The European Commission (EC) has granted Pfizer/BioNTech’s COVID-19 vaccine a conditional marketing authorisation (CMA), under the new name Comirnaty.

The vaccine, also known as BNT162b2, has been authorised for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 16 years of age and older.

The authorisation follows a positive opinion for Comirnaty issued yesterday by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

The authorisation is based on scientific evidence shared by Pfizer/BioNTech as part of the EMA’s rolling review process and the application for the CMA.

This included data from a phase III clinical trial of the vaccine, which demonstrated a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection and also in participants with and without prior SARS-CoV-2 infection.

Pfizer/BioNTech will begin to deliver the first vaccine doses immediately across the EU based on a distribution plan defined by the EC and contract terms.

The EC has previously signed a deal with Pfizer/BioNTech for 200 million doses of a vaccine for COVID-19 in 2020 and 2021, with the option for up to 100 million additional doses.

The Comirnaty doses for Europe will be produced in BioNTech’s manufacturing sites in Germany and in Pfizer’s site in Puurs, Belgium.

“As a company founded and headquartered in the heart of Europe, we are looking forward to delivering the vaccine to Europeans in the upcoming days. We believe that vaccinations may help reduce the number of people in high-risk populations being hospitalised. Moving forward, we will continue to collect efficacy and safety data in participants for an additional two years and test the vaccine against additional mutations that might occur,” said Ugur Sahin, chief executive officer and co-founder of BioNTech.

“I am truly grateful for the collaboration with our partner BioNTech, and to the European Medicines Agency and European Commission for their thorough and efficient review to help us defeat a virus that has already claimed the lives of hundreds of thousands of people in Europe,” said Albert Bourla, chairman and chief executive officer of Pfizer.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026